S-1/A: GRI Bio Seeks $8 Million in Public Offering to Advance Clinical Programs and Meet Nasdaq Requirements

GRI Bio launches a public offering of common stock and warrants aiming to raise $8 million for clinical trials and Nasdaq compliance.

Summary

• GRI Bio is undertaking a public offering to sell up to 3,871,467 shares of common stock, along with Series B-1 and B-2 warrants, at an assumed combined price of $2.066 per share and accompanying warrants.
• The offering also includes pre-funded warrants for purchasers who would exceed beneficial ownership limits.
• The goal is to raise approximately $8 million, with net proceeds intended for working capital and general corporate purposes.
• The offering is expected to terminate on March 15, 2024.
• A.G.P./Alliance Global Partners is acting as the placement agent on a reasonable best efforts basis.
• The company intends to use the net proceeds from this offering for working capital and other general corporate purposes.
• GRI Bio needs to raise at least $6 million to maintain its Nasdaq listing and has until May 20, 2024, to regain compliance with the minimum stockholders' equity requirement.
• The company also needs to maintain a minimum bid price of $1.00 per share by July 3, 2024, to avoid delisting.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively pursuing funding and has ongoing clinical programs, there are significant risks and uncertainties regarding its financial stability and ability to maintain its Nasdaq listing. The 'going concern' warning from the auditors is a major concern.

Positives

• The offering could provide necessary capital to advance GRI Bio's clinical programs.
• Successful completion of the offering may help the company regain compliance with Nasdaq listing requirements.
• The company has commenced enrollment in a Phase 2a biomarker study for GRI-0621 for the treatment of IPF with topline results expected in the second half of 2024.
• The company expects to file an IND with respect to a Phase 1a and 1b trial for GRI-0803 in the first half of 2024.

Negatives

• The offering is on a 'reasonable best efforts' basis, and there is no guarantee that the company will raise the full $8 million.
• Investors face immediate dilution of their investment.
• The company has a history of net losses and may never be profitable.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• Failure to regain compliance with Nasdaq listing requirements could lead to delisting.

Risks

• The company's success is highly dependent on the success of its lead product candidate, GRI-0621.
• Clinical development is a lengthy, complex, and expensive process with an uncertain outcome.
• The company relies on third parties to conduct clinical trials and manufacture product candidates.
• The company may be unable to adequately protect its information systems from cyberattacks.
• The stock price of the company's common stock is expected to be highly volatile.
• Future sales and issuances of the company's securities could result in additional dilution of the percentage ownership of its stockholders and could cause its share price to fall.

Future Outlook

GRI Bio plans to use the net proceeds from the offering for working capital and other general corporate purposes, including advancing its clinical development programs and maintaining Nasdaq compliance. The company expects topline results from its Phase 2a trial of GRI-0621 in IPF patients in the second half of 2024 and intends to file an IND for a Phase 1a/1b trial of GRI-0803 in the first half of 2024.

Industry Context

The announcement comes amid increasing investor interest in biopharmaceutical companies developing therapies for inflammatory, fibrotic, and autoimmune disorders. The company is targeting diseases with significant unmet needs, such as IPF and SLE, where current treatment options are limited or have significant side effects.

Comparison to Industry Standards

• The two approved therapies for IPF, nintedanib (OFEV) and pirfenidone (Esbriet), have been associated with significant side effects leading to poor therapeutic adherence.
• Only two drugs have been approved for lupus in the past 50 years, and new treatment options are sorely needed.
• The company is developing GRI-0621 as an oral formulation of tazarotene, a synthetic retinoid acid receptor-beta and gamma selective agonist, that is approved in the United States for topical treatment of psoriasis and acne.
• The company is developing GRI-0803, a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells, for the treatment of autoimmune disorders.

Stakeholder Impact

• Shareholders face potential dilution from the public offering.
• Employees' job security is tied to the company's ability to secure funding and continue operations.
• Patients with IPF and SLE may benefit from successful development of GRI Bio's product candidates.
• Creditors face increased risk if the company is unable to meet its financial obligations.

Next Steps

• Complete the public offering.
• Advance GRI-0621 through Phase 2a clinical trials and report topline data in the second half of 2024.
• File an IND for GRI-0803 and initiate Phase 1a/1b trials in the first half of 2024.
• Regain compliance with Nasdaq listing requirements by May 20, 2024, and July 3, 2024.

Key Dates

Keywords

public offering, GRI Bio, warrants, common stock, clinical trials, Nasdaq, compliance, biopharmaceutical, equity, financing